Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,842,747 shares, a decrease of 16.6% from the November 15th total of 2,209,414 shares. Based on an average daily volume of 373,735 shares, the short-interest ratio is presently 4.9 days. Approximately 5.9% of the shares of the stock are sold short.

Shares of Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) opened at $2.04 on Tuesday. Rexahn Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $7.10.

Several research firms have weighed in on RNN. Zacks Investment Research raised Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Friday, November 10th. ValuEngine raised Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 2nd. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Rexahn Pharmaceuticals in a report on Monday, August 14th. Finally, Seaport Global Securities reissued a “buy” rating and issued a $13.00 target price on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $13.65.

Several large investors have recently modified their holdings of RNN. Susquehanna International Group LLP purchased a new stake in shares of Rexahn Pharmaceuticals in the second quarter valued at $2,905,000. Sabby Management LLC purchased a new stake in shares of Rexahn Pharmaceuticals in the second quarter valued at $706,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Rexahn Pharmaceuticals in the third quarter valued at $119,000.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/12/rexahn-pharmaceuticals-inc-rnn-sees-significant-decrease-in-short-interest.html.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.